660 related articles for article (PubMed ID: 24421395)
21. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
[TBL] [Abstract][Full Text] [Related]
22. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
23. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Kothandapani A; Gopalakrishnan K; Kahali B; Reisman D; Patrick SM
Exp Cell Res; 2012 Oct; 318(16):1973-86. PubMed ID: 22721696
[TBL] [Abstract][Full Text] [Related]
25. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
26. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
27. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
28. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
29. Combined gene dosage requirement for SWI/SNF catalytic subunits during early mammalian development.
Smith-Roe SL; Bultman SJ
Mamm Genome; 2013 Feb; 24(1-2):21-9. PubMed ID: 23076393
[TBL] [Abstract][Full Text] [Related]
30. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
31. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.
Pan J; McKenzie ZM; D'Avino AR; Mashtalir N; Lareau CA; St Pierre R; Wang L; Shilatifard A; Kadoch C
Nat Genet; 2019 Apr; 51(4):618-626. PubMed ID: 30858614
[TBL] [Abstract][Full Text] [Related]
32. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
33. An essential role for a mammalian SWI/SNF chromatin-remodeling complex during male meiosis.
Kim Y; Fedoriw AM; Magnuson T
Development; 2012 Mar; 139(6):1133-40. PubMed ID: 22318225
[TBL] [Abstract][Full Text] [Related]
34. Structure of the BRK domain of the SWI/SNF chromatin remodeling complex subunit BRG1 reveals a potential role in protein-protein interactions.
Allen MD; Bycroft M; Zinzalla G
Protein Sci; 2020 Apr; 29(4):1047-1053. PubMed ID: 31909846
[TBL] [Abstract][Full Text] [Related]
35. Bromodomain-containing proteins BRD1, BRD2, and BRD13 are core subunits of SWI/SNF complexes and vital for their genomic targeting in Arabidopsis.
Yu Y; Fu W; Xu J; Lei Y; Song X; Liang Z; Zhu T; Liang Y; Hao Y; Yuan L; Li C
Mol Plant; 2021 Jun; 14(6):888-904. PubMed ID: 33771698
[TBL] [Abstract][Full Text] [Related]
36. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart.
Willis MS; Homeister JW; Rosson GB; Annayev Y; Holley D; Holly SP; Madden VJ; Godfrey V; Parise LV; Bultman SJ
Circ Res; 2012 Aug; 111(5):e111-22. PubMed ID: 22740088
[TBL] [Abstract][Full Text] [Related]
37. The SWI/SNF chromatin remodelling complex: Its role in maintaining genome stability and preventing tumourigenesis.
Brownlee PM; Meisenberg C; Downs JA
DNA Repair (Amst); 2015 Aug; 32():127-133. PubMed ID: 25981841
[TBL] [Abstract][Full Text] [Related]
38. BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest.
Bartlett C; Orvis TJ; Rosson GS; Weissman BE
J Cell Physiol; 2011 Aug; 226(8):1989-97. PubMed ID: 21520050
[TBL] [Abstract][Full Text] [Related]
39. Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.
Gao F; Elliott NJ; Ho J; Sharp A; Shokhirev MN; Hargreaves DC
Mol Cell; 2019 Sep; 75(5):891-904.e7. PubMed ID: 31375262
[TBL] [Abstract][Full Text] [Related]
40. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]